DALAVIR Tablets (Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate 50 mg, 300 mg, and 300 mg tablets),Reference product

2 trials

Sponsors

The Government Pharmaceutical Organization

Conditions

Healthy male and female subjects Healthy male and female subjects Bioequivalence fed conditions

Phase 1

An Open Label, Crossover Bioequivalence Study of DALAVIR Tablets of the Government Pharmaceutical Organization, Thailand with TIVICAY (Dolutegravir 50 mg tablets) +EPIVIR (Lamivudine 300 mg tablets) VIREAD (Tenofovir disoproxil fumarate 300 mg tablets) in Healthy Subjects under Fasting Conditions

Active, not recruitingTCTR20210913002

The Government Pharmaceutical OrganizationHealthy male and female subjects Healthy male and female subjects Bioequivalence fed conditions

Start: 2021-11-04Target: 52Updated: 2026-08-03

An Open Label, Crossover Bioequivalence Study of DALAVIR Tablets of the Government Pharmaceutical Organization, Thailand with TIVICAY (Dolutegravir 50 mg tablets) +EPIVIR (Lamivudine 300 mg tablets) VIREAD (Tenofovir disoproxil fumarate 300 mg tablets) in Healthy Subjects under Fasting Conditions

Active, not recruitingTCTR20220331004

The Government Pharmaceutical OrganizationHealthy male and female subjects Healthy male and female subjects Bioequivalence fed conditions

Start: 2022-05-02Target: 52Updated: 2026-08-03